Because of its poor oral bioavailability, foscarnet is administered intravenously. Following intravenous infusion, 14 to 17% of foscarnet is bound to plasma proteins. The concentration of this compound in the vitreous humor is approximately the same as its plasma level. Foscarnet accumulates in bone; this property may account for its bimodal initial half-life of 4 to 8 hours and prolonged terminal elimination half-life of 45 to 130 hours. Foscarnet is eliminated primarily as unchanged drug via glomerular filtration and active tubular secretion.
Was this article helpful?